ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis CEO Sees Big Potential In Biosimilars

ZURICH -(Dow Jones)- Novartis AG (NVS) Chief Executive Joe Jimenez said Tuesday he sees potential in the market for biosimilars, cheaper versions of expensive and complex medicines made from biological matter. "This is a market that is relatively small today, but we expect that by 2020 this could be a 15 to 20 billion dollars segment of the generics business," Jimenez told analysts in a call. "Novartis is uniquely positioned in biosimilars because we have the scientific and medical expertise of a pharmaceutical company and the commercial expertise of a generics company," he said. Novartis has its own generics unit, Sandoz. Biosimilars are imitations of biotech drugs, ones that are basically interchangeable with a previously approved biologic but because of the inherent complexity of the products cannot be termed identical. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
10/23/201407:33:40Novartis 3Q 2014 -- Forecast
10/10/201404:08:25Oxford Biomedica Inks New Collaboration Pact with Novartis
10/03/201411:32:27EU Approves Acquisition of Novartis Animal Health Division by...
09/22/201412:43:39Germany's Merck to Buy Sigma-Aldrich for $17 Billion--2nd Update
09/01/201412:45:13EUROPE MARKETS: Novartis Climbs, Iliad Drops: European Movers
09/01/201412:01:47EUROPE MARKETS: Novartis Up, Iliad Drops: European Movers
09/01/201408:27:44Ruble Hits New Record Low Against Dollar
08/29/201412:46:16Zurich Stocks Rise; Novartis Drug Test Results Eyed -- Market...
08/18/201412:40:12Zurich Stocks Mostly Higher; Swisscom Down -- Market Talk
08/01/201412:26:48LONDON MARKETS: FTSE 100 Slumps For Third Day As Miners, Banks...
07/28/201402:37:21Novartis Gets EU Approval For Glaucoma Drug
07/25/201407:44:11Drug Companies Oppose Moves to Reimburse Off-Label Medicine
07/17/201418:27:37ADR Shares End Lower; SAP Shares Trade Actively
07/16/201418:17:45Novartis 2Q Results -- Forecast
07/15/201417:53:10ADR Shares End Mixed; British American Tobacco Shares Trade Actively
07/15/201416:58:23Novartis, Google Team Up on Lenses -- Update
07/07/201415:20:45Novartis Wins 'Breakthrough' Status for Leukemia Treatment
07/02/201417:32:10ADR Shares End Mixed; Telefonica, Veolia Environnement Shares...
06/19/201409:25:15Actavis Generic Exelon Patch Found to Infringe on Patents
06/18/201417:07:21ADR Shares End Higher

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad